Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023:2663:369-380.
doi: 10.1007/978-1-0716-3175-1_24.

Assays to Monitor Bivalirudin

Affiliations

Assays to Monitor Bivalirudin

Simon Davidson. Methods Mol Biol. 2023.

Abstract

Bivalirudin (Angiomax, Angiox) is a parenteral direct thrombin inhibitor (DTI) that is used for patients with heparin-induced thrombocytopenia (HIT), where heparin cannot be used due to the risk of thrombosis. Bivalirudin is also licensed for use in cardiology procedures (e.g., percutaneous transluminal coronary angioplasty; PTCA). Bivalirudin is a synthetic analogue of hirudin found in the saliva of the medicinal leech and has a relatively short half-life of ~25 min. Several assays can be used to monitor bivalirudin; these include the activated partial thromboplastin time (APTT), activated clotting time (ACT), ecarin clotting time (ECT), an ecarin-based chromogenic assay, thrombin time (TT), the dilute TT, and the prothrombinase-induced clotting time (PiCT). Drug concentrations can also be measured using liquid chromatography tandem mass spectrometry (LC/MS) and clotting or chromogenic-based assays with specific drug calibrators and controls.

Keywords: APTT; Activated clotting time; Activated partial thromboplastin time; Bivalirudin; Dilute thrombin time; Ecarin chromogenic assay; Ecarin clotting time; Heparin-induced thrombocytopenia; Prothrombinase-induced clotting time; Thrombin time.

PubMed Disclaimer

References

    1. De Servi S, Mariani G, Mariani M, D’Urbano M (2013) The bivalirudin paradox: high evidence, low use. J Cardiovasc Med 14:334–341 - DOI
    1. Lund M, Macwan AS, Tunströmer K, Lindahl TL, Boknäs N (2021) Effects of heparin and bivalirudin on thrombin-induced platelet activation: differential modulation of PAR signaling drives divergent prothrombotic responses. Front Cardiovasc Med 29:717835 - DOI
    1. Van Cott EM, Roberts AJ, Dager WE (2017) Laboratory monitoring of parenteral direct thrombin inhibitors. Semin Thromb Hemost 43:270–276 - DOI - PubMed
    1. Warkentin TE, Greinacher A, Koster A (2008) Bivalirudin. Thromb Haemost 99:830–839 - DOI - PubMed
    1. Medicines Agency 2016 Bivalirudin 250 mg powder for concentrate for solution for injection or infusion. http://www.medicinces.org.uk/emc/product/7229/smpc/print . Accessed 26 Sept 2022

LinkOut - more resources